Abstract
An allosteric mechanism refers to the biological regulation process wherein macromolecules propagate the effect of ligand binding at one site to a spatially distant orthosteric locus, thus affecting activity. The theory has remained a trending topic in biology research for over 50 years, since the understanding of allostery is fundamental for gleaning numerous biological processes and developing new drug therapies. In the past two decades, the allosteric paradigm has evolved into more descriptive models, with ever-expanding amounts of experimental data pertaining to newly identified allosteric molecules. The AlloSteric Database (ASD, accessible at http://mdl.shsmu.edu.cn/ASD), which is a comprehensive knowledge repository, has provided the public with integrated information encompassing allosteric proteins, modulators, sites, pathways, and networks to investigate allostery since 2009. In this chapter, we introduce the history and usage of the ASD and give attention to specific applications that have benefited from the ASD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alexandrov V, Lehnert U, Echols N, Milburn D, Engelman D, Gerstein M (2005) Normal modes for predicting protein motions: a comprehensive database assessment and associated Web tool. Protein Sci 14(3):633–643
Armstrong N, Gouaux E (2000) Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron 28(1):165–181
Bian Y, Feng Z, Yang P, Xie XQ (2017) Integrated in silico fragment-based drug design: case study with allosteric modulators on metabotropic glutamate receptor 5. AAPS J 19(4):1235–1248
Changeux JP, Christopoulos A (2016) Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 166(5):1084–1102
Changeux JP, Edelstein SJ (2005) Allosteric mechanisms of signal transduction. Science 308(5727):1424–1428
Chessari G, Woodhead AJ (2009) From fragment to clinical candidate–a historical perspective. Drug Discov Today 14(13–14):668–675
Congreve M, Oswald C, Marshall FH (2017) Applying structure-based drug design approaches to allosteric modulators of GPCRs. Trends Pharmacol Sci 38(9):837–847
Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237
Cuff AL, Sillitoe I, Lewis T, Redfern OC, Garratt R, Thornton J, Orengo CA (2009) The CATH classification revisited–architectures reviewed and new ways to characterize structural divergence in superfamilies. Nucleic Acids Res 37(Database issue):D310–D314
Davis M, Tobi D (2014) Multiple Gaussian network modes alignment reveals dynamically variable regions: the hemoglobin case. Proteins 82(9):2097–2105
de Kloe GE, Bailey D, Leurs R, de Esch IJ (2009) Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov Today 14(13–14):630–646
Dokholyan NV (2016) Controlling allosteric networks in proteins. Chem Rev 116(11):6463–6487
Erman B (2006) The gaussian network model: precise prediction of residue fluctuations and application to binding problems. Biophys J 91(10):3589–3599
Feher VA, Durrant JD, Van Wart AT, Amaro RE (2014) Computational approaches to mapping allosteric pathways. Curr Opin Struct Biol 25:98–103
Fischer S, Olsen KW, Nam K, Karplus M (2011) Unsuspected pathway of the allosteric transition in hemoglobin. Proc Natl Acad Sci U S A 108(14):5608–5613
Goodey NM, Benkovic SJ (2008) Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol 4(8):474–482
Gregory KJ, Dong EN, Meiler J, Conn PJ (2011) Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 60(1):66–81
Huang Z, Zhu L, Cao Y, Wu G, Liu X, Chen Y, Wang Q, Shi T, Zhao Y, Wang Y, Li W, Li Y, Chen H, Chen G, Zhang J (2011) ASD: a comprehensive database of allosteric proteins and modulators. Nucleic Acids Res 39(Database issue):D663–D669
Huang Z, Mou L, Shen Q, Lu S, Li C, Liu X, Wang G, Li S, Geng L, Liu Y, Wu J, Chen G, Zhang J (2014) ASD v2.0: updated content and novel features focusing on allosteric regulation. Nucleic Acids Res 42(Database issue):D510–D516
Huang M, Song K, Liu X, Lu S, Shen Q, Wang R, Gao J, Hong Y, Li Q, Ni D, Xu J, Chen G, Zhang J (2018) AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses. Nucleic Acids Res 46(W1):W451–W458
Jiang L, Zhang X, Chen X, He Y, Qiao L, Zhang Y, Li G, Xiang Y (2015) Virtual screening and molecular dynamics study of potential negative allosteric modulators of mGluR1 from Chinese herbs. Molecules 20(7):12769–12786
Johnstone S, Albert JS (2017) Pharmacological property optimization for allosteric ligands: a medicinal chemistry perspective. Bioorg Med Chem Lett 27(11):2239–2258
Joseph-McCarthy D, Campbell AJ, Kern G, Moustakas D (2014) Fragment-based lead discovery and design. J Chem Inf Model 54(3):693–704. https://doi.org/10.1021/ci400731w
Kew JN, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179(1):4–29
Koshland DE Jr, Nemethy G, Filmer D (1966) Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5(1):365–385
Kumar A, Voet A, Zhang KY (2012) Fragment based drug design: from experimental to computational approaches. Curr Med Chem 19(30):5128–5147
Leach AR, Gillet VJ, Lewis RA, Taylor R (2010) Three-dimensional pharmacophore methods in drug discovery. J Med Chem 53(2):539–558
Li H, Chang YY, Yang LW, Bahar I (2016) iGNM 2.0: the Gaussian network model database for biomolecular structural dynamics. Nucleic Acids Res 44(D1):D415–D422
Lindsley CW, Emmitte KA, Hopkins CR, Bridges TM, Gregory KJ, Niswender CM, Conn PJ (2016) Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. Chem Rev 116(11):6707–6741
Liu Y, Bahar I (2010) Toward understanding allosteric signaling mechanisms in the ATPase domain of molecular chaperones. Pac Symp Biocomput 2010:269–280
Lu S, Zhang J (2018) Small molecule allosteric modulators of G-protein-coupled receptors: drug-target interactions. J Med Chem 62(1):24–45. https://doi.org/10.1021/acs.jmedchem.7b01844
Lu S, Huang W, Zhang J (2014a) Recent computational advances in the identification of allosteric sites in proteins. Drug Discov Today 19(10):1595–1600
Lu S, Li S, Zhang J (2014b) Harnessing allostery: a novel approach to drug discovery. Med Res Rev 34(6):1242–1285
Lu S, Jang H, Muratcioglu S, Gursoy A, Keskin O, Nussinov R, Zhang J (2016) Ras conformational ensembles, allostery, and signaling. Chem Rev 116(11):6607–6665
Monod J, Wyman J, Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88–118
Motlagh HN, Wrabl JO, Li J, Hilser VJ (2014) The ensemble nature of allostery. Nature 508(7496):331–339
Murray CW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem 1(3):187–192
Murzin AG, Brenner SE, Hubbard T, Chothia C (1995) SCOP: a structural classification of proteins database for the investigation of sequences and structures. J Mol Biol 247(4):536–540
Nussinov R (2016) Introduction to protein ensembles and allostery. Chem Rev 116(11):6263–6266
Nussinov R, Tsai CJ (2013) Allostery in disease and in drug discovery. Cell 153(2):293–305
Nussinov R, Tsai CJ (2014) Unraveling structural mechanisms of allosteric drug action. Trends Pharmacol Sci 35(5):256–264
Nussinov R, Tsai CJ (2015) The design of covalent allosteric drugs. Annu Rev Pharmacol Toxicol 55:249–267
Nussinov R, Ma B, Tsai CJ, Csermely P (2013) Allosteric conformational barcodes direct signaling in the cell. Structure 21(9):1509–1521
Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477):548–551
Perutz MF, Rossmann MG, Cullis AF, Muirhead H, Will G, North AC (1960) Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. resolution, obtained by X-ray analysis. Nature 185(4711):416–422
Roy A, Kucukural A, Zhang Y (2010) I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5(4):725–738
Schumacher MA, Zheleznova EE, Poundstone KS, Kluger R, Jones RT, Brennan RG (1997) Allosteric intermediates indicate R2 is the liganded hemoglobin end state. Proc Natl Acad Sci U S A 94(15):7841–7844
Seidel T, Ibis G, Bendix F, Wolber G (2010) Strategies for 3D pharmacophore-based virtual screening. Drug Discov Today Technol 7(4):e203–e270
Shen Q, Wang G, Li S, Liu X, Lu S, Chen Z, Song K, Yan J, Geng L, Huang Z, Huang W, Chen G, Zhang J (2016) ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks. Nucleic Acids Res 44(D1):D527–D535
Shibayama N, Sugiyama K, Tame JR, Park SY (2014) Capturing the hemoglobin allosteric transition in a single crystal form. J Am Chem Soc 136(13):5097–5105
Silva MM, Rogers PH, Arnone A (1992) A third quaternary structure of human hemoglobin A at 1.7-A resolution. J Biol Chem 267(24):17248–17256
Smith RD, Lu J, Carlson HA (2017) Are there physicochemical differences between allosteric and competitive ligands? PLoS Comput Biol 13(11):e1005813
Tobi D (2016) Dynamics and allostery of the ionotropic glutamate receptors and the ligand binding domain. Proteins 84(2):267–277
van Westen GJ, Gaulton A, Overington JP (2014) Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput Biol 10(4):e1003559
Wagner JR, Lee CT, Durrant JD, Malmstrom RD, Feher VA, Amaro RE (2016) Emerging computational methods for the rational discovery of allosteric drugs. Chem Rev 116(11):6370–6390
Wang Q, Zheng M, Huang Z, Liu X, Zhou H, Chen Y, Shi T, Zhang J (2012) Toward understanding the molecular basis for chemical allosteric modulator design. J Mol Graph Model 38:324–333
Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW (2014) Drugs for allosteric sites on receptors. Annu Rev Pharmacol Toxicol 54:165–184
Williams G (2010) Elastic network model of allosteric regulation in protein kinase PDK1. BMC Struct Biol 10:11
Wootten D, Christopoulos A, Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12(8):630–644
Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, Cherezov V, Conn PJ, Stevens RC (2014) Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344(6179):58–64
Yang SY (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15(11–12):444–450
Yelshanskaya MV, Li M, Sobolevsky AI (2014) Structure of an agonist-bound ionotropic glutamate receptor. Science 345(6200):1070–1074
Zhu S, Gouaux E (2017) Structure and symmetry inform gating principles of ionotropic glutamate receptors. Neuropharmacology 112(Pt A):11–15
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Song, K., Zhang, J., Lu, S. (2019). Progress in Allosteric Database. In: Zhang, J., Nussinov, R. (eds) Protein Allostery in Drug Discovery. Advances in Experimental Medicine and Biology, vol 1163. Springer, Singapore. https://doi.org/10.1007/978-981-13-8719-7_4
Download citation
DOI: https://doi.org/10.1007/978-981-13-8719-7_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-8718-0
Online ISBN: 978-981-13-8719-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)